Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Association of the Prescribing Cascade Between Calcium Channel Blockers and Loop Diuretics for Middle-Aged Patients With Hypertension","authors":"Takamasa Sakai,&nbsp;Yuki Kondo,&nbsp;Shinobu Imai","doi":"10.1155/jcpt/9091720","DOIUrl":"https://doi.org/10.1155/jcpt/9091720","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Calcium channel blockers (CCBs) cause peripheral edema. CCB-induced edema is considered diuretic resistant, but many CCB-induced edema cases are treated with diuretics in clinical practice. Therefore, to prevent potentially inappropriate medication and mitigate possible polypharmacy, this study aimed to evaluate the incidence of the potential prescribing cascade and compare it with that of other hypertensive agents among middle-aged patients with hypertension in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using claims data provided by DeSC Healthcare, Inc. Patients prescribed CCBs or renin–angiotensin system (RAS) agents (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers) between April 2015 and September 2020 were included. The primary outcome was the prescription of loop diuretics. Multivariable Cox proportional hazards regression models accounting for competing risks were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for loop diuretic use, adjusting for a set of covariates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From the extracted data, 45,861 and 33,338 patients were prescribed CCBs and RAS agents, respectively. The proportion of female patients was slightly lower among those prescribed RAS agents than among those prescribed CCBs (41.3% vs. 41.1%). After adjustment, patients prescribed CCBs had a higher risk of loop diuretic prescriptions than those prescribed RAS agents (HR [95% CI]: 1.307 [1.055–1.619]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We demonstrated that among middle-aged patients with hypertension, those newly started on CCBs had a 30% higher rate of being newly prescribed loop diuretics within a 1-year period than those on RAS inhibitors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9091720","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and Validation of a Risk Prediction Model for Statin-Associated Muscle Symptoms (SAMS) in Atorvastatin Users","authors":"Jinshi Huang,&nbsp;Zhenyu Fan,&nbsp;Yating Ding","doi":"10.1155/jcpt/3306258","DOIUrl":"https://doi.org/10.1155/jcpt/3306258","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Statin-associated muscle symptoms (SAMS) are a common cause of statin intolerance. This study aimed to develop and validate a risk prediction model for SAMS in atorvastatin users.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective study was conducted on patients who received atorvastatin treatment at a single hospital from January 2017 to December 2024. Based on the treatment initiation period and outcome, patients were assigned to a training set (2017–2021) or a test set (2022–2024). Demographic characteristics, medical history, concurrent medications, and laboratory data (creatine kinase [CK], lipid profiles) measured prior to atorvastatin initiation were collected. The primary outcome was the occurrence of SAMS within 1 year, diagnosed according to established criteria. A nomogram prediction model was constructed using independent risk factors identified from multivariate analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 576 patients, 170 (29.5%) developed SAMS. In the training set (<i>n</i> = 400), multivariate analysis identified male sex as protective (OR: 0.577), while hypothyroidism (OR: 2.390), renal disease (OR: 1.868), polypharmacy (OR: 2.264), fibrate use (OR: 3.742), and higher CK levels (OR: 1.015) were independent risk factors. The nomogram incorporating these factors showed excellent discrimination, with an area under the curve (AUC) of 0.863. Clinical validation in the test set (<i>n</i> = 176) confirmed the model’s robustness, yielding an AUC of 0.801.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The developed nomogram provides a reliable tool for individualized prediction of SAMS risk in patients initiating atorvastatin therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/3306258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “No two classes of biosimilars: Urgent advice to the US Congress and the FDA”","authors":"","doi":"10.1155/jcpt/9806734","DOIUrl":"https://doi.org/10.1155/jcpt/9806734","url":null,"abstract":"<p>S. K. Niazi, “No two classes of biosimilars: Urgent advice to the US Congress and the FDA,” <i>Journal of Clinical Pharmacy and Therapeutics,</i> 47, no. 9 (2022): 1352–1361, https://doi.org/10.1111/jcpt.13743.</p><p>In the article, the conflicts of interest statement is incorrect. The correct statement is shown below:</p><p>“During the preparation and publication of the article, the author was affiliated to the following; US Food and Drug Administration (FDA), The European Medicines Agency (EMA), The Medicines and Healthcare products Regulatory Agency (MHRA), The United States Senate, The White House, The World Health Organization (WHO), RNA Therapeutics Inc, DEI BioPharma.”</p><p>We apologize for this error.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9806734","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149145939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “The Inflation Reduction Act: A boon for the generic and biosimilar industry”","authors":"","doi":"10.1155/jcpt/9858135","DOIUrl":"https://doi.org/10.1155/jcpt/9858135","url":null,"abstract":"<p>S. K. Niazi, “The Inflation Reduction Act: A boon for the generic and biosimilar industry,” <i>Journal of Clinical Pharmacy and Therapeutics</i>, 47, no. 11 (2022): 1738–1751, https://doi.org/10.1111/jcpt.13783.</p><p>In the article, the conflicts of interest statement is incorrect. The correct statement is shown below:</p><p>During the preparation and publication of the article, the author was affiliated to the following: US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), the United States Senate, the White House, the World Health Organization (WHO), RNA Therapeutics Inc, DEI BioPharma.</p><p>We apologize for this error.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9858135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Selection of Andexanet Alfa vs. 4-Factor Prothrombin Complex Concentrate for the Treatment of Life-Threatening Hemorrhage","authors":"Kira Galeano,&nbsp;Rachel E. Culbreth,&nbsp;Jeffrey Brent,&nbsp;Alexandra Amaducci,&nbsp;Alyssa M. Falise,&nbsp;Anna G. Zmuda,&nbsp;Rita Farrah,&nbsp;David Liss,&nbsp;Charlotte Goldfine,&nbsp;Mari Costantini,&nbsp;Sharan Campleman,&nbsp;Paul Wax,&nbsp;Kim Aldy","doi":"10.1155/jcpt/3950388","DOIUrl":"https://doi.org/10.1155/jcpt/3950388","url":null,"abstract":"<p>Andexanet alfa and 4-factor prothrombin complex concentrate (4F-PCC) are used for the reversal of life-threatening hemorrhages associated with oral Factor Xa inhibitors. Limited studies have examined factors influencing reversal agent selection and time to administration. This retrospective, multicenter cohort study evaluated adult patients who presented with a life-threatening hemorrhage associated with oral Factor Xa inhibitors (apixaban or rivaroxaban) and were administered either andexanet alfa or 4F-PCC. The objectives of our study were to analyze whether sociodemographic factors were associated with reversal agent selection, time-to-treatment with the selected reversal agent, and patient outcomes. Among 144 patients (50% andexanet alfa and 50% 4F-PCC), no differences were found in sociodemographic (age, sex, race and ethnicity, insurance, housing status, marital status) or logistical factors (time to reversal agent administration and type of arrival to site hospital) associated with reversal agent selection. There were no differences between andexanet alfa and 4F-PCC for time to reversal agent administration, mortality, mechanical ventilation, length of stay, and thromboembolic events. Factors associated with a longer time to reversal agent administration included patients who were transferred from an outside hospital (RR: 1.27; 95% CI: 1.00, 1.61), patients who received blood products (RR: 1.30; 95% CI: 1.01, 1.68), and patients who were Black compared to non-Hispanic White (RR: 1.34; 95% CI: 1.02, 1.76) after adjusting for age, sex, reversal agent selection (andexanet vs. 4F-PCC), bleeding event type related to Factor Xa inhibitors, insurance, and marital status. In conclusion, there were no statistically significant disparities found in sociodemographic factors associated with the selection of andexanet alfa and 4F-PCC.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/3950388","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRAF/MEK Inhibitor–Associated Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and an FDA Pharmacovigilance Database Study","authors":"Jingyi Zhou,&nbsp;Jiamin Luo,&nbsp;Jianhong Zhu,&nbsp;Xiaofeng Lin,&nbsp;Kexin Yang,&nbsp;Xuechen Chen,&nbsp;Sha Li,&nbsp;Jie Jiang","doi":"10.1155/jcpt/7444836","DOIUrl":"https://doi.org/10.1155/jcpt/7444836","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To evaluate the association between BRAFi/MEKi and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) using disproportionality analysis and case reports.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Case–non-case reports (PubMed/Embase/Cochrane, up to June 2025) and FAERS data (Q1 2004–Q2 2025) were analyzed. Disproportionality signals were assessed using reporting odds ratio (ROR) and information component (IC). Included 154 SJS/TEN cases (17 from the literature, 139 from FAERS: SJS = 95, TEN = 44).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Vemurafenib (BRAFi) and cobimetinib (MEKi) showed significant SJS/TEN risk. Median onset age: 58 years; median latency: 13 days (SJS: 11, TEN: 22). Mortality: 14.0% (18/129 cases; SJS: 8.6%, TEN: 31.8%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BRAFi/MEKi are associated with SJS/TEN risk, necessitating vigilant monitoring and early intervention to mitigate severe outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/7444836","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stress Ulcer Prophylaxis and Clinical Outcomes Among Critically Ill Patients at Selected Hospitals in Addis Ababa, Ethiopia: A Multicenter Prospective Cohort Study","authors":"Asfaw Mamuneh Gebreegziabhear,&nbsp;Gebremicheal Gebreyohanns Kahsay,&nbsp;Afewerki Tesfay Gebremariam,&nbsp;Legese Chelkeba","doi":"10.1155/jcpt/5384059","DOIUrl":"https://doi.org/10.1155/jcpt/5384059","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Even though acid-suppressive medications (ASMs) are significantly important in reducing upper gastrointestinal bleeding (UGIB), there are also concerns regarding increased risk of infection and mortality. In Ethiopia, there are no data about the clinical outcomes of ASMs and associated factors in critically ill patients. Thus, this study aimed to assess the use of stress ulcer prophylaxis (SUP) and clinical outcomes, specifically hospital-acquired infection (HAI) and mortality, in critically ill patients. Thus, the study aims to assess the use of SUP and clinical outcomes in critically ill patients.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A multicenter prospective cohort study was conducted in critically ill patients of all ages from September to November 2021. Logistic and Cox regressions were performed to determine predictors of HAI and mortality. Statistical significance was declared at a 95% confidence interval (95% CI) and &lt;i&gt;p&lt;/i&gt;-value &lt; 0.05.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 229 patients were prospectively followed. The majority were male adults (153, 66.8%). HAI was diagnosed in 47 patients (29.7%) receiving ASMs, and the overall mortality rate was 80 (34.9%). Multivariable logistic regression analysis revealed that stroke (adjusted odds ratio [AOR] = 3.63, 95% CI: 1.30–10.18, &lt;i&gt;p&lt;/i&gt; = 0.014), steroid therapy (AOR = 3.23, 95% CI: 1.45–7.13, &lt;i&gt;p&lt;/i&gt; = 0.004), mechanical ventilation (MV) (AOR = 5.41, 95% CI: 1.23–23.85, &lt;i&gt;p&lt;/i&gt; = 0.026), and SUP (AOR = 2.95, 95% CI: 1.35–6.45, &lt;i&gt;p&lt;/i&gt; = 0.007) were positively associated with HAI during ICU stay. Regarding mortality, MV (AOR = 2.27, 95% CI: 1.14–4.52, &lt;i&gt;p&lt;/i&gt; = 0.019) and hypoperfusion (AOR = 2.77, 95% CI: 1.46–5.27, &lt;i&gt;p&lt;/i&gt; = 0.002) showed positive associations, whereas being pediatric (AOR = 0.49, 95% CI: 0.25–0.97, &lt;i&gt;p&lt;/i&gt; = 0.039) and an ICU stay longer than 1 week (AOR = 0.48, 95% CI: 0.24–0.96, &lt;i&gt;p&lt;/i&gt; = 0.039) were negatively associated with mortality. In Cox proportional hazards regression, a surgical diagnosis (adjusted hazard ratio [AHR] = 3.57, 95% CI: 1.10–11.60, &lt;i&gt;p&lt;/i&gt; = 0.034) was positively associated with HAI. Hypoperfusion (AHR = 2.68, 95% CI: 1.62–4.43, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and MV (AHR = 2.04, 95% CI: 1.10–3.80, &lt;i&gt;p&lt;/i&gt; = 0.025) were positively associated with mortality, while pediatric status (AHR = 0.56, 95% CI: 0.33–0.94, &lt;i&gt;p&lt;/i&gt; = 0.028) was negatively associated.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;HAIs occurred in one-third of patients receiving ASMs. Significant factors associated wi","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5384059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidepressant Adverse Reactions in Adult and Older Adult Populations: A Comparative Study From the Portuguese Pharmacovigilance System (2010–2020)","authors":"Ana Catarina Coelho,&nbsp;Cristina Monteiro,&nbsp;Maria Vaz Patto","doi":"10.1155/jcpt/2448331","DOIUrl":"https://doi.org/10.1155/jcpt/2448331","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The use of antidepressants in Portugal has been increasing, raising concerns about their potential to cause adverse drug reactions (ADRs), particularly in vulnerable populations. This study aimed to characterize all ADRs associated with antidepressant use reported between January 1, 2010, and December 31, 2020, and to compare these findings between adults and older adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective descriptive study was conducted using data from the Portuguese Pharmacovigilance System (PPS) database. The analysis considered age, sex, pharmacological group, ADR seriousness, and type of reporter.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 751 ADRs cases were identified (496 in adults; 255 in older adults). Women accounted for the majority of ADRs in both groups, with 70.97% (<i>n</i> = 352) of cases in adults and 67.84% (<i>n</i> = 173) in older adults. Selective serotonin reuptake inhibitors (SSRIs) were the primary contributors to ADRs in adults (33.43%), while tricyclic antidepressants (TCAs) were the leading cause in older adults (46.86%). Serious ADRs were predominant in both groups. In adults, marketing authorization holders (MAHs) were the primary reporters, whereas physicians and pharmacists played a more active role in reporting ADRs in older adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the need for continuous monitoring and reporting of antidepressant-related ADRs, given their significant association with serious adverse outcomes. The predominance of TCAs in ADR reports and the high proportion of serious cases underscore the need for careful prescribing of these drugs. However, the absence of denominator data limits the assessment of the true incidence and relative risk of ADRs associated with antidepressants. Even though these results support the role of real-world data in improving medication safety and informing clinical and regulatory decision-making.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2448331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Potentially Inappropriate Medication Use in Patients Aged ≥ 80 Years With Atrial Fibrillation According to STOPP Criteria Version 3 and 2023 Beers Criteria","authors":"Ying Bai,&nbsp;Jianqi Wang,&nbsp;Guangyao Li,&nbsp;Zhen Zhou","doi":"10.1155/jcpt/7149111","DOIUrl":"https://doi.org/10.1155/jcpt/7149111","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; What is Known and Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The presence of potentially inappropriate medications (PIMs) is associated with drug-related harmful effects, including adverse drug events, elevated rates of hospital readmissions, and higher mortality rates. Patients aged ≥ 80 years with atrial fibrillation (AF) often present with multiple comorbidities and polypharmacy; however, evidence regarding PIM usage in this specific population is still limited. Consequently, this study investigated the prevalence of PIMs in patients with AF aged ≥ 80 years and identified the factors associated with PIM use.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective cross-sectional study was conducted at Beijing Tongren Hospital and included patients aged ≥ 80 years with AF who were discharged from the internal medicine wards between July 2021 and July 2024. PIMs in discharge medications were identified using the STOPP criteria Version 3 and 2023 Beers criteria. Patients who received at least one PIM were categorized into the PIM group. Consistency between the two screening tools was evaluated using the kappa test. Variables collected included gender, age, estimated glomerular filtration rate (eGFR), length of stay, age-adjusted Charlson Comorbidity Index (aCCI), Barthel index, comorbidities, and the number of medications. Multivariable binary logistic regression was used to identify factors correlated with the incidence of PIMs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results and Discussion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among 425 patients aged ≥ 80 years with AF, the prevalence rates of at least one PIM were 35.5% and 73.4% according to the STOPP criteria version 3 and 2023 Beers criteria, respectively. Among patients who received PIMs, the majority received only one PIM, accounting for 27.8% and 40.9% according to the STOPP criteria Version 3 and 2023 Beers criteria, respectively. Benzodiazepines, antiplatelets, and z-drugs were the top three PIMs according to STOPP criteria version 3, whereas diuretics, rivaroxaban, and benzodiazepines were the top three PIMs according to 2023 Beers criteria. A poor concordance was observed between the two criteria (&lt;i&gt;k&lt;/i&gt; = 0.117, 95% confidence interval: 0.050–0.184; &lt;i&gt;p&lt;/i&gt; = 0.01). The number of medications was associated with the prevalence of PIMs for both criteria (&lt;i&gt;p&lt;/i&gt; &lt; 0.001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; What is New and Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The prevalence of PIMs among patients aged ≥ 80 years with AF was relatively high. The STOPP criteria Version 3 identified a lower prevalence of PIMs than the 2023 Beers criteria, and the agree","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/7149111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardamonin Impairs Glutamine-Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase","authors":"Danyun Li,&nbsp;Peiguang Niu,&nbsp;Yanting Zhu,&nbsp;Huajiao Chen,&nbsp;Qiuhua Ding","doi":"10.1155/jcpt/5621631","DOIUrl":"https://doi.org/10.1155/jcpt/5621631","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic reprogramming contributes to ovarian cancer progression and therapeutic resistance, and glutamine utilization plays a critical role in supporting tumor growth and maintaining redox homeostasis. Cardamonin, a naturally occurring chalcone compound, has demonstrated antitumor activity in several malignancies; however, its effects on glutamine metabolism in ovarian cancer remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Human ovarian cancer SKOV3 and A2780 cells were cultured under glutamine-sufficient and glutamine-deprived conditions and treated with cardamonin to evaluate its antiproliferative effects. Cell viability was assessed by CCK-8 assay. Apoptosis and intracellular reactive oxygen species (ROS) levels were measured by flow cytometry. The expression of glutaminase and mTORC1 pathway-related proteins was examined by western blotting. In addition, Raptor-deficient SKOV3 cells were used to further investigate the underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cardamonin significantly inhibited ovarian cancer cell proliferation, with more pronounced suppressive effects observed under glutamine-rich conditions. In addition, cardamonin increased apoptotic cell populations and promoted ROS accumulation in SKOV3 cells. Western blot analysis demonstrated that cardamonin decreased glutaminase expression and reduced phosphorylation of S6K1. Similar suppression of glutaminase expression was observed following rapamycin treatment. Furthermore, Raptor deficiency reduced glutaminase expression and attenuated the inhibitory effects of cardamonin on glutaminase expression and S6K1 phosphorylation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that cardamonin impairs glutamine-dependent ovarian cancer cell growth through inhibiting glutaminase expression, which is associated with blockade of the mTORC1 signaling pathway. Collectively, the present study supports glutamine metabolism as a potential therapeutic target of cardamonin in ovarian cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5621631","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}